Vistagen Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Vistagen Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 6.2% y 55.4%, respectivamente, mientras que el BPA aumentará de grow a 24.2%.

Información clave

6.2%

Tasa de crecimiento de los beneficios

24.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.6%
Tasa de crecimiento de los ingresos	55.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	14 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines

Nov 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:VTGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	3	-72	-104	-81	2
3/31/2026	N/A	-65	-68	-61	2
3/31/2025	0	-62	-53	-56	4
3/31/2024	1	-30	-29	-29	4
12/31/2023	1	-32	-26	-26	N/A
9/30/2023	1	-35	-31	-31	N/A
6/30/2023	0	-46	-42	-42	N/A
3/31/2023	0	-59	-50	-50	N/A
12/31/2022	0	-64	-58	-58	N/A
9/30/2022	0	-65	-60	-60	N/A
6/30/2022	1	-60	-55	-55	N/A
3/31/2022	1	-49	-45	-45	N/A
12/31/2021	2	-62	-35	-35	N/A
9/30/2021	1	-56	-28	-28	N/A
6/30/2021	1	-47	-16	-15	N/A
3/31/2021	1	-42	-12	-12	N/A
12/31/2020	1	-16	-10	-9	N/A
9/30/2020	0	-17	-9	-9	N/A
6/30/2020	N/A	-19	-14	-14	N/A
3/31/2020	N/A	-22	-16	-16	N/A
12/31/2019	N/A	-24	-17	-17	N/A
9/30/2019	N/A	-26	-16	-16	N/A
6/30/2019	N/A	-28	-16	-16	N/A
3/31/2019	N/A	-26	-15	-15	N/A
12/31/2018	N/A	-24	-14	-14	N/A
9/30/2018	N/A	-20	-12	-12	N/A
6/30/2018	N/A	-18	-10	-10	N/A
3/31/2018	N/A	-16	-9	-9	N/A
12/31/2017	N/A	-14	-8	-8	N/A
9/30/2017	1	-13	N/A	-7	N/A
6/30/2017	1	-12	N/A	-8	N/A
3/31/2017	1	-12	N/A	-7	N/A
12/31/2016	1	-18	N/A	-7	N/A
9/30/2016	N/A	-19	N/A	-6	N/A
6/30/2016	N/A	-24	N/A	-6	N/A
3/31/2016	N/A	-51	N/A	-5	N/A
12/31/2015	N/A	-48	N/A	-4	N/A
9/30/2015	N/A	-46	N/A	-4	N/A
6/30/2015	N/A	-39	N/A	-3	N/A
3/31/2015	N/A	-14	N/A	-3	N/A
12/31/2014	N/A	-9	N/A	-2	N/A
9/30/2014	N/A	-8	N/A	-2	N/A
6/30/2014	N/A	-8	N/A	-2	N/A
3/31/2014	N/A	-3	N/A	-2	N/A
12/31/2013	N/A	-5	N/A	-3	N/A
9/30/2013	N/A	-21	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: VTGN se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: VTGN se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: VTGN se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: VTGNSe prevé que los ingresos de la empresa (54.2% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: VTGNSe prevé que los ingresos de la empresa (54.2% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de VTGN se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Vistagen Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Forecast to breakeven in 2026

Price target decreased to US$2.82

Consensus forecasts updated

Forecast to breakeven in 2025

Consensus forecasts updated

Recent updates

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Vistagen Therapeutics, Inc. to Report Q3, 2024 Results on Feb 13, 2024

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Vistagen Therapeutics, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer

New major risk - Shareholder dilution

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Vistagen Appoints Cindy Anderson as Chief Financial Officer

Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD)

Vistagen Therapeutics, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Share price stability

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

Vistagen Therapeutics, Inc., Annual General Meeting, Sep 25, 2023

Vistagen Therapeutics, Inc. Announces New Mechanism of Action Data from Preclinical Tissue Distribution Study in Laboratory Rats

Vistagen Therapeutics, Inc. Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry into the Brain

Vistagen Therapeutics, Inc. Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Vistagen Therapeutics, Inc. Announces Retirement of Jerrold D. Dotson, Chief Financial Officer, Effective on or About August 31, 2023

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

VistaGen Therapeutics, Inc. Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

Vistagen Provides Nasdaq Compliance Update

Forecast to breakeven in 2026

VistaGen Therapeutics, Inc. to Report Q3, 2023 Results on Feb 07, 2023

VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) completed the acquisition of Pherin Pharmaceuticals, Inc.

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

VistaGen Therapeutics, Inc. Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Price target decreased to US$2.82

VistaGen Therapeutics, Inc. to Report Q2, 2023 Results on Nov 10, 2022

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects

Vistagen Therapeutics, Inc. Announces Completion of an Interim Analysis of PALISADE-2

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Vistagen Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance of Minimum Bid Price

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 14, 2022

CEO & Director recently bought US$103k worth of stock

Consensus forecasts updated

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$3.36

Vistagen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug Ph94b

VistaGen drops 80% as late-stage study for anxiety therapy fails

Consensus revenue estimates fall by 32%

No longer forecast to breakeven

VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer

VistaGen Therapeutics, Inc. to Report Fiscal Year 2022 Results on Jun 23, 2022

CEO & Director exercised options to buy US$120k worth of stock.

VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety Disorder

VistaGen Therapeutics, Inc. Appoints Reid Adler as Chief Legal Officer

Forecast to breakeven in 2025

VistaGen Therapeutics, Inc. to Present Preclinical Data on Lead Candidate PH94B At Upcoming Scientific Congresses

Forecast to breakeven in 2025

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Forecast to breakeven in 2025

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VistaGen Therapeutics, Inc. Announces Clinical Trials Update

VistaGen Therapeutics, Inc. to Report Q3, 2022 Results on Feb 10, 2022

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

CFO, VP & Secretary recently sold US$94k worth of stock

Consensus forecasts updated

Consensus revenue estimates increase to US$1.58m

CFO, VP & Secretary exercised options to buy US$304k worth of stock.